Type 1 diabetes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

  NCT04177303· Hellenic Institute for the Study of Sepsis· Updated 3 Nov 2026

  “It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.”Registry text, quoted unchanged. Source

• Terminated

  Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes

  NCT06854861· St. Olavs Hospital· Updated 19 Oct 2026

  “The study was terminated due toa combination of: 1. At best minimal effect on insulin absorption 2. Withdrawal of funding as the patent application for using glucagon to enhance subcutaneous insulin absorption was not approved.”Registry text, quoted unchanged. Source

• Terminated

  Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D)

  NCT06315725· McGill University Health Centre/Research Institute of the McGill University Health Centre· Updated 6 Oct 2026

  “The study was terminated due to recruitment difficulties. Only three participants enrolled within two years due to specific insulin pump requirements. Recruitment was therefore discontinued before the planned sample size was reached.”Registry text, quoted unchanged. Source

• Withdrawn

  Clinican BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes

  NCT07491471· Stanford University· Updated 24 Sept 2026

  “Change in research priority”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Suspended

  Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya.

  NCT05944731· Foundation for Innovative New Diagnostics, Switzerland· Updated 21 Sept 2026

  “funding issues”Registry text, quoted unchanged. Source

• Terminated

  Effects of HBO on Glucose in Patients With DM

  NCT04261738· Legacy Health System· Updated 26 Aug 2026

  “Facility closure, awaiting relocation”Registry text, quoted unchanged. Source

• Withdrawn

  Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

  NCT05985135· Mayo Clinic· Updated 5 Aug 2026

  “Changed IRB number”Registry text, quoted unchanged. Source

• Terminated

  Societal Burden Associated With Type 1 Diabetes in Canada

  NCT06786130· PeriPharm· Updated 30 Jul 2026

  “Recruitment.”Registry text, quoted unchanged. Source

• Terminated

  Siplizumab in T1DM

  NCT05574335· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 28 Jul 2026

  “Prior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lymphodepletion. The pharmaceutical partner decided not to reopen its own T1D trial and ceased development of siplizumab in autoimmunity.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

  NCT07922330· AstraZeneca· Source

• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Eli Lilly and Company· Source

• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Eli Lilly and Company· Source

• Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

  NCT05854069· Vanderbilt University Medical Center· Source

• Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

  NCT06111586· Sanofi· Source

• Relationship Between Insulin Dose and Complications in Type 1 Diabetes

  NCT07911033· Rachel Miller· Source

• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· AstraZeneca· Source

• Closed Loop and Education for Hypoglycemia Awareness Restoration

  NCT06325202· Milton S. Hershey Medical Center· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Cholesterol Lowering and Residual Risk in Diabetes, Type 1

  NCT05641753· NYU Langone Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 30
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Overcoming Cross-Sensitivity for the Accurate Identification of Acetone, Isopropanol, and Clinical Mixtures Using a MEMS Dual-Sensor Array and Multi-task Deep Learning.

  ACS Sens, Oct 2026

• Accelerated Brain Aging in Type 1 Diabetes Across Painful and Painless Peripheral Neuropathy: MRI-Based Brain Age Estimates From Deep Learning.

  Diabetes, Oct 2026

• GAT-BiGRU: explainable multi-task temporal graph learning for glucose forecasting, hypoglycemia risk, and counterfactual insulin adjustment.

  J Am Med Inform Assoc, Sept 2026

• Data Augmentation via Digital Twins to Develop Personalized Deep Learning Glucose Prediction Algorithms for Type 1 Diabetes in Poor Data Context.

  IEEE Trans Biomed Eng, Jul 2026

• Deep learning analysis of ECGs detects Cardiovascular-Kidney-Metabolic syndrome burden in people with diabetes: a report from the Silesia Diabetes-Heart Project.

  Cardiovasc Diabetol, Jun 2026

• Diabetes Management Through Glucose Dynamics Analysis Network: A Novel Approach for Accurate Blood Glucose Level Forecasting.

  Diabetes Obes Metab, Jun 2026

• Deep learning-powered quantification of endocrine cells and CD3+ T cells in the natural history of type 1 diabetes.

  Diabetologia, May 2026

• Systematic Review on Deep Learning Algorithms for Blood Glucose Forecasting in Type 1 Diabetes.

  IEEE J Biomed Health Inform, May 2026

• PathViT Model for Automated Disease Classification from Skeletal Muscle Histopathology.

  Am J Pathol, Nov 2025

• Evaluating the Effect of Input Features on Deep Learning Models for Blood Glucose Forecasting.

  Annu Int Conf IEEE Eng Med Biol Soc, Jul 2025

See which targets of this disease your abstract mentions, and go to the people working on them.